Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant What is This Site Help Center Crisis
Powered By

Top 5 search results for "Tafinlar" in Resources. To see all results and access other features, sign up for free.

Posts
Resources
Q&A
People
Groups
Treatments
NSCLC Targeted Therapy: 8 Facts
... Osimertinib (Tagresso) Sunvozertinib (Zegfrovy) ALK inhibitors Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) ROS1 inhibitors Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) BRAF inhibitors Dabrafenib (Tafinlar ...
NSCLC Targeted Therapy: 8 Facts
... Osimertinib (Tagresso) Sunvozertinib (Zegfrovy) ALK inhibitors Alectinib (Alecensa) Brigatinib (Alunbrig) Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) ROS1 inhibitors Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) BRAF inhibitors Dabrafenib (Tafinlar ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... and osimertinib (Tagrisso) ALK inhibitors, such as alectinib (Alecensa), brigatinib (Alunbrig), ceritinib (Zykadia), crizotinib (Xalkori), and lorlatinib (Lorbrena) ROS1 inhibitors, such as ceritinib (Zykadia), crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib (Augtyro), and taletrectinib (Ibtrozi) BRAF inhibitors, such as dabrafenib (Tafinlar ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... and osimertinib (Tagrisso) ALK inhibitors, such as alectinib (Alecensa), brigatinib (Alunbrig), ceritinib (Zykadia), crizotinib (Xalkori), and lorlatinib (Lorbrena) ROS1 inhibitors, such as ceritinib (Zykadia), crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib (Augtyro), and taletrectinib (Ibtrozi) BRAF inhibitors, such as dabrafenib (Tafinlar ...
6 Lung Cancer Mutations and Treatments That Target Them
... BRAF inhibitors include: Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) These therapies may be prescribed alone or with another form of targeted therapy called MEK inhibitors, which include: Trametinib (Mekinist) Binimetinib (Mektovi) 5. TP53 MutationsTumor protein p53, or TP53, is a gene that encodes for the protein p53. ...
6 Lung Cancer Mutations and Treatments That Target Them
... BRAF inhibitors include: Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) These therapies may be prescribed alone or with another form of targeted therapy called MEK inhibitors, which include: Trametinib (Mekinist) Binimetinib (Mektovi) 5. TP53 MutationsTumor protein p53, or TP53, is a gene that encodes for the protein p53. ...
Lung Cancer Treatment Options
... Inhibitors used to treat these mutations include: Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) Binimetinib (Mektovi) is often used alongside encorafenib. It’s a kinase inhibitor that helps prevent cancer cell growth.KRAS G12C InhibitorsThe KRAS gene can control how fast cancer cells divide and spread. ...
Lung Cancer Treatment Options
... Inhibitors used to treat these mutations include: Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) Binimetinib (Mektovi) is often used alongside encorafenib. It’s a kinase inhibitor that helps prevent cancer cell growth.KRAS G12C InhibitorsThe KRAS gene can control how fast cancer cells divide and spread. ...
How Does Targeted Therapy for Lung Cancer Work?
... Targeted therapies for BRAF and other proteins include: Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) BRAF inhibitors are sometimes combined with another medication that targets a pathway known as MEK. ...
How Does Targeted Therapy for Lung Cancer Work?
... Targeted therapies for BRAF and other proteins include: Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) BRAF inhibitors are sometimes combined with another medication that targets a pathway known as MEK. ...